Loading company
QuidelOrtho Corp
QDEL · Nasdaq · ·
Next earnings: November 4, 2026
$10.60-2.1%Sep 29 close
- 1M
- -28.1%
- 6M
- -30.5%
- 1Y
- -64.0%
- 5Y
- -92.5%
QDEL · Nasdaq · ·
Next earnings: November 4, 2026
$10.60-2.1%Sep 29 close
QuidelOrtho Corp is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 28, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 28, 2026 | 3 months toJun 29, 2025 | Change |
|---|---|---|---|
| Total Revenue | $630.9M | $613.9M | +2.77% |
| Profit | -$92.9M | -$255.4M | +63.63% |
| Profit per share | -$1.36 | -$3.77 | +63.93% |
| Free Cash Flow | -$136.1M | -$84.3M | -61.45% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter performance demonstrated QuidelOrtho’s underlying strength and the benefits of our diversified portfolio, with solid results across our core franchises and regions, with the exception of China. Demand headwinds in China related to the proposed IVD pricing guidelines and a softer global respiratory environment are continuing to impact our business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Corporation With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from QuidelOrtho Corp’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
QuidelOrtho Corp has no earnings call transcript available.